Enanta Pharmaceuticals (ENTA) Set to Announce Quarterly Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) will be announcing its earnings results after the market closes on Monday, November 26th. Analysts expect the company to announce earnings of $1.21 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

ENTA opened at $78.99 on Friday. Enanta Pharmaceuticals has a 12 month low of $46.86 and a 12 month high of $127.77. The firm has a market cap of $1.53 billion, a P/E ratio of 86.80 and a beta of 1.04.

Several research analysts recently commented on ENTA shares. BidaskClub raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday. ValuEngine cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 8th. Zacks Investment Research cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 8th. JMP Securities reissued a “buy” rating and set a $120.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, July 31st. Finally, UBS Group cut Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 8th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $104.00.

In other news, insider Tim Ocain sold 25,000 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $83.64, for a total transaction of $2,091,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Nathalie Adda sold 4,155 shares of the company’s stock in a transaction dated Thursday, September 20th. The stock was sold at an average price of $95.32, for a total value of $396,054.60. Following the transaction, the vice president now directly owns 4,155 shares of the company’s stock, valued at $396,054.60. The disclosure for this sale can be found here. Corporate insiders own 10.56% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by WKRB News and is owned by of WKRB News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.wkrb13.com/2018/11/24/enanta-pharmaceuticals-enta-set-to-announce-quarterly-earnings-on-monday.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Further Reading: Can systematic risk be avoided?

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply